Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Dasiglucagon in Children with Congenital Hyperinsulinism
2024-514007-34-00Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of dasiglucagon in congenital hyperinsulinism (HI), sponsored by Zealand Pharma. Primary endpoint: Adverse events. Started Aug 2024; status: completed.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2024-514007-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514007-34-00.